Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | UGCG | Q16739 | 2/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865302 | 1.00 | TSHR (0.45) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL2512920 | 1.00 | TSHR (0.45) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL600300 | 0.79 | TSHR (0.52) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL9416308 | 0.79 | TSHR (0.44) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL22241751 | 0.79 | BCHE (0.51) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL9416306 | 0.79 | TSHR (0.44) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL9416309 | 0.79 | TSHR (0.44) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL22091837 | 0.76 | TSHR (0.64) | TSHRPOLBTAAR1HTTLMNA | |
| SCHEMBL2933597 | 0.74 | TSHR (0.50) | TSHRTAAR1LMNAPDE4DBCHE | |
| SCHEMBL880187 | 0.74 | TSHR (0.50) | TSHRTAAR1LMNAPDE4DBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-211847754-U | Crude entecavir intermediate-7 column chromatography pretreatment line | 济南爱思医药科技有限公司 | 2020-11-03 | — | — | CN | claimed |
| CN-113024490-B | Preparation method of entecavir intermediate | 南通诺泰生物医药技术有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113024574-B | Preparation method of oxadicyclohexane compound | 南通诺泰生物医药技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-113024574-A | Preparation method of oxabicyclohexane compound | 南通诺泰生物医药技术有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-113024490-A | Preparation method of entecavir intermediate | 南通诺泰生物医药技术有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-211847754-U | Crude entecavir intermediate-7 column chromatography pretreatment line | 济南爱思医药科技有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-211586604-U | Entecavir intermediate-7 coarse material synthetic line | 济南爱思医药科技有限公司 | 2020-09-29 | — | — | CN | disclosed |
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2552931-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | GILEAD PHARMASSET LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752422-A1 | Stereoselective synthesis of phosphorus containing actives | Gilead Pharmasset LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-0481754-B1 | Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines | SQUIBB & SONS INC (US) | 1997-08-20 | — | — | EP | disclosed |
| CN-1030916-C | Process for preparing hydroxymethyl (methylenecyclopentyl) purines and pyrimidines | SQUIBB & SONS INC (US) | 1996-02-07 | — | — | CN | disclosed |
| US-5340816-A | Viricides; administering to treat herpes simplex virus, varicella zoster virus and human cytomegalovirus infections | E. R. SQUIBB & SONS, INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5206244-A | Viricides | E. R. SQUIBB & SONS, INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0481754-A2 | Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines | E.R. Squibb & Sons, Inc. (US) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | TSHR 3793/4885POLB 515/4885TAAR1 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.